Press coverage about Selecta Biosciences (NASDAQ:SELB) has been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Selecta Biosciences earned a media sentiment score of 0.02 on Accern’s scale. Accern also gave media stories about the company an impact score of 43.2490163604033 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Several research analysts recently commented on the stock. ValuEngine downgraded shares of Selecta Biosciences from a “hold” rating to a “sell” rating in a research report on Tuesday, September 26th. Zacks Investment Research downgraded shares of Selecta Biosciences from a “hold” rating to a “sell” rating in a research report on Wednesday, August 16th. Finally, Canaccord Genuity set a $25.00 target price on shares of Selecta Biosciences and gave the company a “buy” rating in a research report on Friday, August 11th. Two analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Selecta Biosciences has a consensus rating of “Hold” and a consensus price target of $27.75.
Selecta Biosciences (SELB) opened at 19.75 on Friday. The stock’s market capitalization is $435.96 million. Selecta Biosciences has a 12-month low of $11.95 and a 12-month high of $28.00. The stock’s 50 day moving average is $18.81 and its 200 day moving average is $18.81.
Selecta Biosciences (NASDAQ:SELB) last issued its earnings results on Friday, August 11th. The company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($0.86) by $0.01. Selecta Biosciences had a negative return on equity of 88.31% and a negative net margin of 1,277.76%. The company had revenue of $0.03 million for the quarter. Equities research analysts forecast that Selecta Biosciences will post ($3.17) EPS for the current fiscal year.
In related news, Director Amir Nashat sold 42,610 shares of the stock in a transaction that occurred on Wednesday, September 20th. The stock was sold at an average price of $20.03, for a total transaction of $853,478.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO David Siewers sold 16,424 shares of the stock in a transaction that occurred on Wednesday, September 20th. The shares were sold at an average price of $20.00, for a total value of $328,480.00. Following the sale, the chief financial officer now owns 2,194 shares of the company’s stock, valued at approximately $43,880. The disclosure for this sale can be found here. In the last quarter, insiders have sold 355,658 shares of company stock valued at $6,955,732. 41.90% of the stock is currently owned by corporate insiders.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.
Receive News & Ratings for Selecta Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.